Different Molecular Levels of Post-induction Minimal Residual Disease May Predict Hematopoietic Stem Cell Transplantation Outcome in Adult Philadelphia-negative Acute Lymphoblastic Leukemia

Overview

Journal Blood Cancer J

Date 2014 Jul 12

PMID 25014772

Citations 23

Authors

R Bassan

O Spinelli

E Oldani

T Intermesoli

M Tosi

B Peruta

E Borlenghi

E M Pogliani

E Di Bona

V Cassibba

A M Scattolin

C Romani

F Ciceri

A Cortelezzi

G Gianfaldoni

D Mattei

E Audisio

A Rambaldi

Affiliations

Soon will be listed here.

Citing Articles

Need for consensus on primary end points and efficacy definitions in trials for adult acute lymphoblastic leukemia.

Wieduwilt M Blood Adv. 2024; 8(15):4234-4238.

PMID: 38717864 PMC: 11372386. DOI: 10.1182/bloodadvances.2023010449.

The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.

Jabbour E, Short N, Jain N, Haddad F, Welch M, Ravandi F J Hematol Oncol. 2023; 16(1):22.

PMID: 36927623 PMC: 10018889. DOI: 10.1186/s13045-023-01409-5.

MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?.

Gokbuget N Hematology Am Soc Hematol Educ Program. 2022; 2021(1):718-725.

PMID: 35158373 PMC: 8824253. DOI: 10.1182/hematology.2021000224.

Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods.

Kotrova M, Koopmann J, Trautmann H, Alakel N, Beck J, Nachtkamp K Blood Adv. 2022; 6(10):3006-3010.

PMID: 35026836 PMC: 9131918. DOI: 10.1182/bloodadvances.2021006727.

Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years: NILG ALL 10/07.

Bassan R, Pavoni C, Intermesoli T, Spinelli O, Tosi M, Audisio E Blood Cancer J. 2020; 10(11):119.

PMID: 33188164 PMC: 7666128. DOI: 10.1038/s41408-020-00383-2.

References

Buckley S, Appelbaum F, Walter R . Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia. Bone Marrow Transplant. 2012; 48(5):630-41. DOI: 10.1038/bmt.2012.139. View

Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M . Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013; 119(15):2728-36. PMC: 3720844. DOI: 10.1002/cncr.28136. View

Lankester A, Bierings M, van Wering E, Wijkhuijs A, de Weger R, Wijnen J . Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia. 2010; 24(8):1462-9. DOI: 10.1038/leu.2010.133. View

Ribera J, Oriol A, Morgades M, Montesinos P, Sarra J, Gonzalez-Campos J . Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the.... J Clin Oncol. 2014; 32(15):1595-604. DOI: 10.1200/JCO.2013.52.2425. View

Leung W, Pui C, Coustan-Smith E, Yang J, Pei D, Gan K . Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood. 2012; 120(2):468-72. PMC: 3398757. DOI: 10.1182/blood-2012-02-409813. View

Gokbuget N, Kneba M, Raff T, Trautmann H, Bartram C, Arnold R . Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012; 120(9):1868-76. DOI: 10.1182/blood-2011-09-377713. View

Brentjens R, Davila M, Riviere I, Park J, Wang X, Cowell L . CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013; 5(177):177ra38. PMC: 3742551. DOI: 10.1126/scitranslmed.3005930. View

Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B . Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009; 113(18):4153-62. DOI: 10.1182/blood-2008-11-185132. View

Bruggemann M, Raff T, Kneba M . Has MRD monitoring superseded other prognostic factors in adult ALL?. Blood. 2012; 120(23):4470-81. DOI: 10.1182/blood-2012-06-379040. View

10.

Spinelli O, Peruta B, Tosi M, Guerini V, Salvi A, Zanotti M . Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica. 2007; 92(5):612-8. DOI: 10.3324/haematol.10965. View

11.

Gokbuget N, Basara N, Baurmann H, Beck J, Bruggemann M, Diedrich H . High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood. 2011; 118(13):3504-11. DOI: 10.1182/blood-2011-01-329441. View

12.

Dominietto A, Pozzi S, Miglino M, Albarracin F, Piaggio G, Bertolotti F . Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. Blood. 2007; 109(11):5063-4. DOI: 10.1182/blood-2007-02-072470. View

13.

Goldstone A, Richards S, Lazarus H, Tallman M, Buck G, Fielding A . In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional.... Blood. 2007; 111(4):1827-33. DOI: 10.1182/blood-2007-10-116582. View

14.

Topp M, Gokbuget N, Zugmaier G, Degenhard E, Goebeler M, Klinger M . Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012; 120(26):5185-7. DOI: 10.1182/blood-2012-07-441030. View